INO Profile
novio Pharmaceuticals, Inc., a pioneering biotechnology firm based in Plymouth Meeting, Pennsylvania, specializes in the research, development, and commercialization of DNA-based medicines designed to combat diseases linked to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative DNA medicines platform revolves around SynCon, which optimizes DNA sequences targeting specific antigens, and the CELLECTRA smart devices technology, facilitating efficient delivery of DNA plasmids.
Inovio Pharmaceuticals is actively engaged in conducting clinical trials and planning studies across a broad spectrum of medical conditions. These include HPV-associated precancers such as cervical, vulvar, and anal dysplasia, as well as HPV-related cancers like head and neck, cervical, anal, penile, vulvar, and vaginal cancers. The company also focuses on other HPV-associated disorders, recurrent respiratory papillomatosis, glioblastoma multiforme, prostate cancer, HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever.
The company collaborates extensively with numerous partnersand organizations, including AstraZeneca, The Bill & Melinda Gates Foundation, Thermo Fisher Scientific, and the National Institutes of Health, among others. These collaborations underscore Inovio Pharmaceuticals' commitment to advancing its DNA-based vaccine technologies and treatments for a range of global health challenges.
Founded in 1979, Inovio Pharmaceuticals continues to expand its global footprint through strategic partnerships and collaborations aimed at furthering its research efforts and advancing potential breakthroughs in the field of DNA medicine. Headquartered in Pennsylvania, the company remains dedicated to pioneering advancements in therapeutic solutions that address critical unmet medical needs worldwide.
|
